Bovie Medical Corporation To Conduct Conference Call On J-Plasma™ Technology

Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced Jeff Rencher, Vice President of Sales and Marketing will host a conference call at 11:00 am EDST on Monday, September 26 ^th to discuss Bovie’s J-Plasma technology.

Stockholders and interested parties may participate in the call by dialing 1 [phone] or 1-678-302-3571. Please call in a few minutes before the conference call is scheduled to begin. A recording of the live conference call will be immediately available after the call has concluded for the next 30 days. The dial-in number to listen to the recording is 1 [phone] or 1-678-302-3562 then enter access code 4804300#. Press 4 to listen and enter the confirmation number 201109205106963#.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2010. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

1 2 Next › Last »